

Quintiles acquires Novella, retains leadership team

17 September 2013 | News | By BioSpectrum Bureau



Singapore: Global CRO Quintiles has completed the acquisition of Novella Clinical, a full-service clinical research organization focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors.

With the transaction now officially closed, Novella will now focus its efforts on leveraging Quintiles' global resources and capabilities with the expertise and personal attention of Novella to continue to deliver the high-quality services customers have come to expect from both companies.

"We are extremely pleased to have completed the acquisition of Novella and look forward to working together to increase our collective opportunities with emerging oncology and medical device companies," said Ms Paula Brown Stafford, president, Clinical Development, Quintiles.

"With the transaction now officially closed, we will focus our efforts on leveraging Quintiles' global resources and capabilities with the expertise and personal attention of Novella to continue to deliver the high-quality services customers have come to expect from both companies," she added.

Now known as Novella Clinical, a Quintiles company; Novella will operate as an unit within Quintiles, retaining its existing leadership team as well as its specialized customer focus.